Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription 15.06.2020 1 Am J Clin Oncol 3 Am J Respir Crit Care Med 3 Ann Oncol 1 Ann Surg Oncol 2 Ann Thorac Surg 1 Anticancer Res 1 BMC Cancer 2 Br J Cancer 1 Cancer Cell 2 Cancer Lett 1 Cancer Res 1 Cancer Sci 1 Clin Exp Metastasis 3 Clin Lung Cancer 2 Eur J Cancer 1 Hum Pathol 1 Int J Cancer 3 J Cancer Res Clin Oncol 1 J Surg Oncol 12 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 JAMA Oncol 11 Lung Cancer 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. CLAMON G, Zeitler W, An J, Hejleh TA, et al
   Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review.
   Am J Clin Oncol. 2020 Jun 5. doi: 10.1097/COC.0000000000000720.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

2. QUAIFE SL, Ruparel M, Dickson JL, Beeken RJ, et al
   Reply to: Improving Lung Cancer Screening Uptake.
   Am J Respir Crit Care Med. 2020 Jun 11. doi: 10.1164/rccm.202005-1699.
   PubMed        
   
   
3. WILSON DO
   Improving Lung Cancer Screening Uptake.
   Am J Respir Crit Care Med. 2020 Jun 11. doi: 10.1164/rccm.202004-1486.
   PubMed        
   
   
4. PENNYCUICK A, Janes SM
   On the Origin of Lung Cancers.
   Am J Respir Crit Care Med. 2020;201:646-647.
   PubMed        
   
   

   
   Ann Oncol

5. PENTHEROUDAKIS G
   Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).
   Ann Oncol. 2020 Jun 2. pii: S0923-7534(20)39865.
   PubMed        
   
   
6. ZHAI H, Moore D, Jamal-Hanjani M
   Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma.
   Ann Oncol. 2020;31:169-170.
   PubMed        
   
   
7. MAZZOTTA M, Filetti M, Rossi A, Roberto M, et al
   Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
   Ann Oncol. 2020;31:440-441.
   PubMed        
   
   

   
   Ann Surg Oncol

8. LETICA-KRIEGEL AS, Leinwand JC, Sonett JR, Gorenstein LA, et al
   50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
   Ann Surg Oncol. 2020;27:205-213.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

9. DENLINGER CE, Gibney BC
   Selective Delivery of Adjuvant Chemotherapy to Healthier Patients.
   Ann Thorac Surg. 2020;109:1520-1521.
   PubMed        
   
   
10. ZHANG Y, Fu F, Chen H
    Management of ground-glass opacities in the lung cancer spectrum.
    Ann Thorac Surg. 2020 Jun 7. pii: S0003-4975(20)30894.
    PubMed         Abstract available
    
    

    
    Anticancer Res

11. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. LIU Y, Zhu Y, Bai L, Chen F, et al
    Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.
    BMC Cancer. 2020;20:520.
    PubMed         Abstract available
    
    

    
    Br J Cancer

13. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed         Abstract available
    
    
14. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed         Abstract available
    
    

    
    Cancer Cell

15. COLES GL, Cristea S, Webber JT, Levin RS, et al
    Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
    Cancer Cell. 2020 May 22. pii: S1535-6108(20)30253.
    PubMed         Abstract available
    
    

    
    Cancer Lett

16. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed         Abstract available
    
    
17. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed         Abstract available
    
    

    
    Cancer Res

18. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed         Abstract available
    
    

    
    Cancer Sci

19. DENG M, Liu B, Zhang Z, Chen Y, et al
    The knockdown of GPSM2 promotes the metastasis of non-small cell lung cancer by inducing the expression of Snail.
    Cancer Sci. 2020 Jun 10. doi: 10.1111/cas.14519.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

20. REDDY SP, Dowell JE, Pan E
    Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients.
    Clin Exp Metastasis. 2020 Jun 4. pii: 10.1007/s10585-020-10040.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

21. FRIEDLAENDER A, Liu SV, Passaro A, Metro G, et al
    The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Apr 30. pii: S1525-7304(20)30105.
    PubMed         Abstract available
    
    
22. MARMARELIS ME, Langer CJ
    Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30010.
    PubMed         Abstract available
    
    
23. GUERINI AE, Borghetti P, Filippi AR, Bonu ML, et al
    Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30167.
    PubMed        
    
    

    
    Eur J Cancer

24. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed         Abstract available
    
    
25. SADATE A, Occean BV, Beregi JP, Hamard A, et al
    Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography.
    Eur J Cancer. 2020;134:107-114.
    PubMed         Abstract available
    
    

    
    Hum Pathol

26. BUTNOR KJ, Pavlisko EN, Sporn TA, Roggli VL, et al
    Mesothelioma of the tunica vaginalis testis.
    Hum Pathol. 2019 Jul 31. pii: S0046-8177(19)30133.
    PubMed         Abstract available
    
    

    
    Int J Cancer

27. VELAZQUEZ-KRONEN R, Gilbert ES, Linet MS, Moysich KB, et al
    Lung cancer mortality associated with protracted low-dose occupational radiation exposures and smoking behaviors in U.S. radiologic technologists, 1983-2012.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33141.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

28. WEN Z, Zhao Y, Fu F, Hu H, et al
    Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter.
    J Cancer Res Clin Oncol. 2020;146:1603-1613.
    PubMed         Abstract available
    
    
29. ZHAO M, Chen Z, Zheng Y, Liang J, et al
    Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
    J Cancer Res Clin Oncol. 2020;146:1463-1472.
    PubMed         Abstract available
    
    
30. ZHOU H, Sun Y, Xiu W, Han J, et al
    Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 9. pii: 10.1007/s00432-020-03282.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

31. GILL RR, Barlow J, Jaklitsch MT, Schmidlin EJ, et al
    Image-guided video-assisted thoracoscopic resection (iVATS): Translation to clinical practice-real-world experience.
    J Surg Oncol. 2020;121:1225-1232.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

32. SRINATHAN S
    Is ventilatory efficiency the next new thing in prehabilitation?
    J Thorac Cardiovasc Surg. 2020;159:e323-e324.
    PubMed        
    
    
33. SESTI J, Paul S
    Commentary: Known unknowns and unknown unknowns: The case of the indeterminate margin.
    J Thorac Cardiovasc Surg. 2020;159:2042.
    PubMed        
    
    
34. CHEN-YOSHIKAWA TF
    Commentary: A journey of a thousand miles begins with a single step.
    J Thorac Cardiovasc Surg. 2020;159:2092-2093.
    PubMed        
    
    
35. PASS HI
    Commentary: Not only SMART clinically, but translationally!
    J Thorac Cardiovasc Surg. 2020;159:2094-2095.
    PubMed        
    
    
36. DE PERROT M
    Commentary: Is thoracic cage volume a new parameter for clinical staging in mesothelioma?
    J Thorac Cardiovasc Surg. 2020;159:2520-2521.
    PubMed        
    
    
37. BOFFA DJ, Salazar M
    Commentary: How surprising.
    J Thorac Cardiovasc Surg. 2020;159:2483-2484.
    PubMed        
    
    
38. BRUNELLI A
    Commentary: The power of indeterminacy.
    J Thorac Cardiovasc Surg. 2020;159:2041.
    PubMed        
    
    
39. ANDRADE R
    Commentary: Why do uniportal video-assisted thoracoscopic lobectomy?
    J Thorac Cardiovasc Surg. 2020;159:2496-2497.
    PubMed        
    
    
40. HOANG CD
    Commentary: Surgeon versus mesothelioma in a thoracic cage match.
    J Thorac Cardiovasc Surg. 2020;159:2522-2523.
    PubMed        
    
    
41. GILES AE, Kidane B
    Commentary: Know your enemy-Understanding futility in the battle against malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;159:2523-2524.
    PubMed        
    
    
42. DENLINGER CE
    Commentary: Durable activity of a tyrosine kinase inhibitor in lung cancer.
    J Thorac Cardiovasc Surg. 2020 Apr 23. pii: S0022-5223(20)30985.
    PubMed        
    
    
43. HOANG CD
    Commentary: Smoke or fire? Resected lung cancer in never-smokers.
    J Thorac Cardiovasc Surg. 2020 Apr 10. pii: S0022-5223(20)30795.
    PubMed        
    
    

    
    J Thorac Oncol

44. UPRETY D, Mandrekar SJ, Wigle D, Roden AC, et al
    Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.
    J Thorac Oncol. 2020 Jun 6. pii: S1556-0864(20)30425.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

45. KAS B, Talbot H, Ferrara R, Richard C, et al
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 11. pii: 2766806. doi: 10.1001/jamaoncol.2020.1634.
    PubMed         Abstract available
    
    

    
    Lung Cancer

46. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed         Abstract available
    
    
47. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed         Abstract available
    
    
48. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed         Abstract available
    
    
49. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed         Abstract available
    
    
50. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed         Abstract available
    
    
51. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed         Abstract available
    
    
52. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed         Abstract available
    
    
53. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed         Abstract available
    
    
54. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed         Abstract available
    
    
55. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed         Abstract available
    
    
56. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed         Abstract available
    
    

    
    PLoS One

57. LI B, Dai C, Wang L, Deng H, et al
    A novel drug repurposing approach for non-small cell lung cancer using deep learning.
    PLoS One. 2020;15:e0233112.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: